

December 18, 2020  
 Symbio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Completion, Monthly Exercise Status and Large Volume Exercise of the 51<sup>st</sup> Stock Acquisition Rights  
 (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment**

TOKYO, Japan, December 18, 2020—Symbio Pharmaceuticals Limited (JASDAQ: 4582) announces the monthly exercise status and the large volume exercise of the 51<sup>st</sup> Stock Acquisition Rights, and that the exercise of all 51<sup>st</sup> stock acquisition rights issued and allotted to EVO FUND on March 16, 2020, are completed as of today.

**I. The Large Volume Exercise**

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 51 <sup>st</sup> Stock Acquisition Rights
(2)	Number of issued shares from the previous disclosure	1,100,000 Shares
(3)	Number of stock acquisition rights being exercised from the previous disclosure and the ratio to the entire issue	1,100,000 Units (Ratio to the total number of stock acquisition rights issued 3,000,000 units : 36.67%)
(4)	Number of unexercised stock acquisition rights as of the previous disclosure	1,100,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	0 Units

**(6) Exercise status from the previous disclosure**

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
December 4 (Fri)	-	-	362	-
December 7 (Mon)	-	-	362	-
December 8 (Tue)	-	-	362	-
December 9 (Wed)	-	-	362	-
December 10 (Thu)	-	-	362	-
December 11 (Fri)	-	-	357	-
December 14 (Mon)	-	-	357	-
December 15 (Tue)	-	-	357	-
December 16 (Wed)	-	-	357	-
December 17 (Thu)	-	-	357	-
December 18 (Fri)	1,100,000	-	343	1,100,000

※Number of issued shares at the end of the previous month : 36,499,331 shares [of which 28,618 shares are treasury shares]

## II. Monthly Exercise Status

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 51 <sup>st</sup> Stock Acquisition Rights
(2)	Number of issued shares from the beginning of the month	1,700,000 Shares
(3)	Number of stock acquisition rights being exercised from the beginning of the month and the ratio to the entire issue	1,700,000 Units (Ratio to the total number of stock acquisition rights issued 3,000,000 units : 56.67%)
(4)	Number of unexercised stock acquisition rights as of the beginning of the month	1,700,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	0 Units

## (6) Exercise status from the beginning of the month

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
December 1 (Tue)	-	-	353	-
December 2 (Wed)	-	-	353	-
December 3 (Thu)	600,000	-	353	600,000
December 4 (Fri)	-	-	362	-
December 7 (Mon)	-	-	362	-
December 8 (Tue)	-	-	362	-
December 9 (Wed)	-	-	362	-
December 10 (Thu)	-	-	362	-
December 11 (Fri)	-	-	357	-
December 14 (Mon)	-	-	357	-
December 15 (Tue)	-	-	357	-
December 16 (Wed)	-	-	357	-
December 17 (Thu)	-	-	357	-
December 18 (Fri)	1,100,000	-	343	1,100,000

※Number of issued shares at the end of the previous month : 36,499,331 shares [of which 28,618 shares are treasury shares]

## (7) Status concerning restriction on exercise (Status concerning compliance with exercise restrictions under Article 434 of the Listing Regulations)

①	Total number of shares to be delivered upon the exercise of all series of stock acquisition rights	②	Number of listed shares at the time of the payment for the issuance	③	Exercise ratio on exercise limit(①/②)
	1,700,000 Shares		28,122,581 Shares		6.04%